Human Oncology & Pathogenesis Program

The Andy Minn Lab

Research

Andy Minn, MD, PhD
Andy Minn, MD, PhD
Lab Head; Chair, Immuno-Oncology Program

In the Minn Lab, we interrogate the intersection of chronic inflammation and interferon signalling, virus mimicry pathways, and immune checkpoint resistance in tumor cells — integrating cellular, molecular and translational approaches. Our goal is to convert mechanistic insights into new therapeutic combinations that potentiate anti-tumor immunity.

Projects

  • Investigate how chronic inflammation and persistent interferon signaling alters local and systemic anti-tumor immunity
  • Discover immunotherapy resistance mechanisms driven by cellular adaptation to chronic inflammation
  • Understand mechanisms of inflammatory “memory” and how it impacts immune responses
  • Explore the role of chronic virus mimicry in immunotherapy response
  • Develop therapeutic strategies targeting immune dysfunction from chronic inflammation

Publications Highlights

Mathew D, Marmarelis ME, Foley C, Bauml JM, Ye D, Ghinnagow R, Ngiow SF, Klapholz M, Jun S, Zhang Z, Zorc R, Davis CW, Diehn M, Giles JR, Huang AC, Hwang WT, Zhang NR, Schoenfeld AJ, Langer CJ, Wherry EJ, Minn AJ. Combined JAK Inhibition and PD-1 Immunotherapy for Non Small Cell Lung Cancer Patients. Science. 2024 Jun;384(6702):eadf1329. 

Memon D, Schoenfeld AJ, Ye D, Fromm G, Rizvi H, Zhang X, Keddar MR, Mathew D, Yoo KJ, Qiu J, Lihm J, Miriyala J, Sauter JL, Luo J, Chow A, Bhanot UK, McCarthy C, Vanderbilt CM, Liu C, Abu-Akeel M, Plodkowski AJ, McGranahan N, Łuksza M, Greenbaum BD, Merghoub T, Achour I, Barrett JC, Stewart R, Beltrao P, Schreiber TH, Minn AJ, Miller ML, Hellmann MD. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell. 2024 Feb 12;42(2):209-224.e9. https://doi.org/10.1016/j.ccell.2023.12.013

View All Publications

People

Andy Minn, MD, PhD

Andy Minn, MD, PhD

Lab Head; Chair, Immuno-Oncology Program

  • The Minn Lab investigates how cancers evolve under chronic inflammation and persistent immune pressure to acquire resistance to immunotherapies, with the goal of developing innovative therapies to restore anti-tumor immunity.
  • University of Chicago

Members

Ellen Cangialosi
Assistant to Chair, Lab Admin
Nathan Dangle
Graduate Research Assistant
Yuwei Qi
Research Scholar
Marco Vincenzo Russo
Lab Manager
Claire Shao
Research Scholar
Shangshang Wang
Research Scholar